A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction

Journal of Clinical Pharmacology

Volumn , Issue , 2016, Pages 936-947

  Nguyen, Elaine ^a   Weeda, Erin R ^a   White, C Michael ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

f channel inhibitor; heart failure with reduced ejection fraction; ivabradine; neprilysin inhibitor; sacubitril; valsartan

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 CARBOXY 1 BUTYLCARBAMOYL)PROPIONIC ACID; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENKEPHALINASE INHIBITOR; EPLERENONE; HYDRALAZINE; ISOSORBIDE DINITRATE; IVABRADINE; KETOCONAZOLE; LOSARTAN; MEMBRANE METALLOENDOPEPTIDASE; METOPROLOL SUCCINATE; OMAPATRILAT; PLACEBO; SACUBITRIL; SACUBITRIL PLUS VALSARTAN; SPIRONOLACTONE; TICAGRELOR; VALSARTAN;

CARDIOVASCULAR MORTALITY; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART RATE; HOSPITALIZATION; HUMAN; HYPOTENSION; MORBIDITY; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTOLIC HEART FAILURE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84978405418     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.677     Document Type: Review

References (70)

1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–322.
2. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147–239.
3. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.
4. Cohn JN, Archibald DG, Phil M, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med. 1986;314:1547–1552.
5. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303–310.
6. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349–1355.
7. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007.
8. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet. 1999;353:9–13.
9. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582–1587.
10. Granger CB, McMurray JJ, Yusurf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;363:772–776.
11. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators.A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675.
12. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-convertign-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767–771.
13. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail. 1999;5:178–187.
14. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–2057.
15. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–717.
16. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.
17. Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol. 1997;29:709–715.
18. Mcalister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150:784–794.
19. Silke B. Beta-blockade in CHF: pathophysiological considerations. Eur Heart J. 2006;8(Suppl C):C13–C18.
20. Difrancesco D. Pacemaker mechanisms in cardiac tissue. Annu Rev Physiol. 1993;55:455–472.
21. Perez O, Gay P, Franqueza L et al. Effects of the two enantiomers, S-16257-2 and S-16260-2, of a new bradycardic agent on guinea-pig isolated cardiac preparations. Br J Pharmacol. 1995;115:787–794.
22. Bucchi A, Baruscotti M, Difrancesco D. Current-dependent block of rabbit sino-atrial node I(f) channels by ivabradine. J Gen Physiol. 2002;120:1–13.
23. Tendera M, Talajic M, Robertson M, et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). Am J Cardiol. 2011;107:805–811.
24. Ragueneau I, Laveille C, Jochemsen R, Resplandy G, Funck-Brentano C, Jaillon P. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther. 1998;64:192–203.
25. Corlanor [package insert]. Thousand Oaks, CA: Amgen Inc; 2015.
26. Entresto [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015.
27. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321–328.
28. Abassi Z, Karram T, Ellaham S, Winaver J, Hoffman A. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol Ther. 2004;102:223–241.
29. Lee CYW, Burnett JC Jr. Natriuretic peptides and therapeutic applications. Heart Fail Rev. 2007;12:131–142.
30. Correa de Sa DD, Chen HH. The role of natiruetic peptides in heart failure. Curr Cardiol Rep. 2008;10:182–189.
31. Rubattu S, Sciarreta S, Valenti V, Stanzione R, Volpe M. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular disease. Am J Hypertens. 2008;21:733–741.
32. Buggey J, Mentz RJ, DeVore AD, Velazquez EJ. Antiogtensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact. J Card Fail. 2015;21:741–750.
33. Judge P, Haynes R, Landray MJ, Baigent C. Neprilysin inhibition in chronic kidney disease. Nephrol Dial Transplant. 2015;30:738–743.
34. Gu J, Noe A, Chandra P, Al-Fayoumi S, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50:401–414.
35. Lillyblad MP. Dual angiotensin receptor and neprilyin inhibition in chronic systolic heart failure: understanding the new PARADIGM. Ann Pharmacother. 2015;49:1237–1251.
36. McMurrary JJ. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. Eur J Heart Fail. 2015;17:242–247.
37. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32–43.
38. McDowell G, Nicholls DP. The endopeptidase inhibitor, candoxatril, and its therapeutic potential in the treatment of chronic cardiac failure in man. Exp Opin Invest Drugs. 1999;8:79–84.
39. McDowell G, Coutie W, Shaw C, Buchanan KD, Struthers AD, Nicholls DP. The effect of neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmacol. 1997;43:329–332.
40. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure. Circulation. 2002;106:920–926.
41. Center for Drug Evaluation and Research Division of Cardio-Renal Drug Products. Food and Drug Administration. Joint Statistical-Clinical Review NDA 21-188. http://www.fda.gov/ohrms/dockets/ac/02/briefing/3877B2_03_FDA-Medial-Statistical.htm. Accessed September 4, 2015.
42. Kobalava Z, Averkov O, Meray I, et al. Natriuretic peptide inhibition in the presence of angiotensin receptor blockade following short-term treatment with LCZ696 in heart failure patients: effect on ANP, BNP, NT-proBNP, and cGMP. Eur Heart J. 2011;32(abstract suppl):784–785.
43. Jordaan P, Albrecht D, Feng A, et al. Changes in RAAS (renin angiotensin aldosterone system) biomarkers in stable chronic heart failure (HF) patients following short-term angiotensin receptor neprilysin inhibitor (ARNI) treatment. SA Heart. 2011;8:236.
44. Pham AQ, Patel Y, Gallagher B. LCZ696 (angiotensin-neprilysin inhibition): the new kid on the heart failure block? J Pharm Pract. 2015;28:137–145.
45. European Medicines Agency. Procoralan (ivabradine): Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000597/WC500043590.pdf. Accessed October 22, 2015.
46. Cervetto L, Demontis GC, Gargini C. Cellular mechanisms underlying the pharmacological induction of phosphenes. Br J Pharmacol. 2007;150:383–390.
47. Francois-bouchard M, Simonin G, Bossant MJ, Boursier-Neyret C. Simultaneous determination of ivabradine and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl. 2000;745:261-269.
48. Ayalasomayajula S, Jordaan P, Pal P, et al. Assessment of drug interaction potential between LCZ696 and warfarin. Hypertension. 2013;62:A448.
49. Shitara Y. Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions. Drug Metab Pharmacokinet. 2011;26:220–227.
50. Romaine SPR, Bailey KM, Hall AS, Balmforth AJ. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenom J. 2010;10:1–11.
51. Fox K, Ford I, Steg PG, Tendera M, Ferrari R, BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807–816.
52. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875–885.
53. Böhm M, Borer J, Ford I, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2013;102:11–22.
54. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996;94:2807–2816.
55. Gheorghiade M, Albert NM, Curtis AB, et al. Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF. Congest Heart Fail. 2012;18:9-17.
56. Komajda M, Böhm M, Borer J, et al. Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure. Eur J Heart Fail. 2013;15:79–84.
57. Tavazzi L, Swedberg K, Komajda M, et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. Eur J Heart Fail. 2013;15:1296–303.
58. Beautiful Study Group, Ferrari R, Ford I, Fox K, Steg PG, Tendera M. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction—baseline characteristics of the study population. Cardiology. 2008;110:271–282.
59. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). Eur J Heart Fail. 2010;12:75–81.
60. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.
61. Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011;124:544–554.
62. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237.
63. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329–1338.
64. Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:2385–2395.
65. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840–844.
66. McMurray JJ, Packer M, Desai AK, et al. Angiotensin-nepriysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
67. McMurray JJ, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Herat Fail. 2013;15:1062–1073.
68. Desai AS, McMurray JJ, Packer M, et al. Effect of angiotensin-receptor neprilyin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015;36:1990–1997.
69. Unger EF, Food and Drug Administration. NDA 207620 Approval Letter. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/207620Orig1s000ltr.pdf. Accessed September 4, 2015.
70. McMurray JJ, Packer M, Desai AS, et al. Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2014;16:814–825.